Chengdu-based biopharmaceutical manufacturer selling drugs in China.
Chengdu-based biopharmaceutical manufacturer selling drugs in China.
Moat: none
Headquarters: Chengdu, China · Employees: 1,480
Size Chengdu Easton Biopharmaceuticals (688513.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 2110th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.82 on 18 Nov 2026.
Performance Over six months the shares fell 33.1%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 2.0% over the last twelve months (peer median +7.7%); the operating margin is 12.9% (peer median 8.7%).
Valuation It trades at 24.6× forward earnings against a peer median of 18.3× (4th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.30B | CN¥1.32B | CN¥1.34B | CN¥1.11B | CN¥1.16B |
| Revenue growth | — | -1% | +21% | -4% | — |
| Gross profit | CN¥1.03B | CN¥940M | CN¥956M | CN¥840M | CN¥933M |
| EBITDA | n/a | CN¥276M | CN¥253M | CN¥229M | CN¥217M |
| Net income | CN¥273M | CN¥284M | CN¥238M | CN¥227M | CN¥247M |
| Free cash flow | CN¥170M | CN¥179M | CN¥146M | CN¥100.0M | -CN¥187M |
| Capital expenditure | CN¥90.5M | CN¥86.3M | CN¥117M | CN¥175M | CN¥339M |
| Total debt | CN¥263M | CN¥191M | CN¥156M | CN¥270M | CN¥117M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688513.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.9% | -5.0% | 3rd lowest of 21 |
| 6-month return | -33.1% | -10.6% | 3rd lowest of 21 |
| Distance from 52-week high | -51.8% | -32.1% | 3rd lowest of 21 |
| Revenue growth (TTM) | -2.0% | +7.7% | 6th lowest of 19 |
| Operating margin | 12.9% | 8.7% | 9th highest of 19 |
| Forward P/E | 24.6× | 18.3× | 4th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 4.4% | 2.5% | 6th most demanding of 14 |
| Growth delivered (Del g) | +7.7% | +6.5% | 7th highest of 14 |
| Hurdle (Req g minus delivered) | -3.3 pp | -3.6 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +6.4 pp | +0.1 pp | 4th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |